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Mycoplasma pneumoniae causes a sig-nificant burden of disease in children as 
both upper and lower respiratory tract infec-
tions (URTIs and LRTIs). A positive phar-
yngeal polymerase chain reaction (PCR) or 
serology for M. pneumoniae can be found in 
4–39% of children hospitalized with commu-
nity-acquired pneumonia (CAP).1 Since the 
introduction of the pneumococcal conjugate 
vaccine, M. pneumoniae has been reported to 
be the most common bacterial cause of CAP 
among hospitalized U.S.  children.2
M. pneumoniae is transmitted by 
respiratory droplets through close contact. 
The incubation period can be as long as 1–3 
weeks. M. pneumoniae infection is gener-
ally mild and self-limiting. However, patients 
of every age can develop severe CAP or 
extrapulmonary manifestations. The lack 
of a cell wall makes M. pneumoniae resist-
ant to cell wall synthesis inhibitors such as 
β-lactam antibiotics. Antibiotics effective 
against M. pneumoniae include macrolides, 
tetracyclines and fluoroquinolones.3 How-
ever, a Cochrane review4 concluded that there 
is insufficient evidence to draw any definitive 
conclusions about the efficacy of antibiot-
ics for M. pneumoniae LRTI in children. 
Macrolides are extensively used worldwide, 
and this has led to alarming resistance rates 
among Streptococcus pneumoniae and M. 
pneumoniae.5 Reported macrolide-resistant 
M. pneumoniae (MRMP) prevalence is par-
ticularly high in Asia with over 90% in some 
regions, resulting in therapy refractory M. 
pneumoniae CAP.5 Efficacy data and tai-
lored prescription of antibiotic treatment 
are needed to minimize further selection of 
MRMP. Unfortunately, currently, there is no 
single diagnostic method that confirms active 
M. pneumoniae infection in CAP.
This review focuses on the diagnosis 
of M. pneumoniae infections in children and 
discusses clinical and microbiologic features 
that may help identifying M. pneumoniae as 
the cause of CAP.
CLINICAL ASSESSMENT
Clinical assessment – the art in diag-
nosing M. pneumoniae infection
The term “walking pneumonia” had 
been introduced to denote the mild form of 
CAP in most patients with M. pneumoniae 
infection. These patients can generally be 
managed in primary care. Physicians often 
rely solely on clinical suspicion in such cases.
EPIDEMIOLOGY
M. pneumoniae occurs endemi-
cally worldwide. Infections can be observed 
throughout the year, but tend to be more com-
mon in summer and early fall. Epidemic peaks 
can be observed every 3–7 years, whereas 
climate and geography may not be relevant.5,6 
Outbreaks of M. pneumoniae infections have 
been reported within families, schools, institu-
tions and military bases. Clinicians should be 
particularly aware of M. pneumoniae as poten-
tial cause of CAP during M. pneumoniae epi-
demics. M. pneumoniae infections can occur 
in all ages. However, M. pneumoniae CAP is 
reported to be most frequent among school-
age children 5–15 years of age.1,2,5
SIGNS AND SYMPTOMS
In addition to the presentation at 
school-age, children with CAP due to M. 
pneumoniae have been found to present 
with a significantly longer duration of fever 
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compared with other CAP patients.7 A fast-
and-frugal clinical decision tree provided 
a rapid probability estimate of the cause of 
CAP in children: determining the preceding 
duration of fever combined with the age of the 
child allowed identification of patients at high 
risk for M. pneumoniae CAP, that is, children 
with CAP who have had fever > 2 days and 
who were > 3 years of age.7 The decision tree 
placed 72% of all patients with M. pneumo-
niae infection into the high-risk group.
Apart from fever, clinical signs and 
symptoms of M. pneumoniae infection vary 
widely. The commonest symptoms are a sore 
throat and a (typically nonproductive) cough. 
Other symptoms may be the absence of 
wheeze and the presence of chest pain.8 Symp-
toms typically develop over several days and 
an intractable cough often persists for weeks to 
months. However, another Cochrane review8 
concluded that M. pneumoniae infection can-
not be reliably diagnosed based on clinical 
symptoms alone. Nevertheless, a combination 
of age and clinical features rather than spe-
cific findings may aid clinicians in identifying 
patients at high risk for M. pneumoniae CAP.
EXTRAPULMONARY 
MANIFESTATIONS
Additional clinical features of M. 
pneumoniae infection include extrapulmo-
nary manifestations, which can affect almost 
every organ, including the skin and the nerv-
ous, hematologic, cardiovascular and mus-
culoskeletal system.9 These manifestations 
are caused either by direct local effects of M. 
pneumoniae after dissemination or indirect 
immune-mediated effects.
Skin manifestations occur in up to 25% 
of all M. pneumoniae infections, including 
mainly nonspecific exanthems, urticaria, and 
(less commonly) erythema nodosum. There are 
also rare but distinct pediatric M. pneumoniae-
associated skin disorders such as erythema 
multiforme, Stevens-Johnson syndrome, and 
M. pneumoniae-associated mucositis.9
Encephalitis and Guillain-Barré syn-
drome constitute the most severe neurologic 
manifestations, where M. pneumoniae infec-
tion is thought to be causative in up to 10% and 
21% of patients, respectively.10,11 We recently 
demonstrated that M. pneumoniae triggers 
antibodies against the major myelin antigen 
galactocerebroside (GalC), and showed that 
anti-GalC IgG is critical for the development 
of Guillain-Barré syndrome following M. 
pneumoniae infection.11 Because the detection 
rate of M. pneumoniae by PCR in cerebrospi-
nal fluid (CSF) of M. pneumoniae encephalitis 
patients is low (0–14%), a significant propor-
tion of the cases may be immune-mediated as 
well.10 In fact, we also demonstrated anti-GalC 
IgG antibodies in serum and CSF of patients 
with encephalitis12 and severe  Guillain-Barré 
syndrome with additional CNS symptoms,13 
which suggests that these antibodies are also 
involved in the development of M. pneumo-
niae-associated CNS disease.
The presence of extrapulmonary man-
ifestations in children with CAP significantly 
increases the probability of M. pneumoniae 
infection.
LABORATORY PARAMETERS
CAP patients with uncomplicated M. 
pneumoniae infection often have normal or 
only slightly raised absolute leukocyte and 
neutrophil counts, as well as lower C-reactive 
protein levels than children with CAP caused 
by other bacterial organisms.5,7
CHEST RADIOGRAPH
The radiographic presentation of 
“atypical” pneumonia due to M. pneumoniae 
is extremely variable. Bilateral, diffuse inter-
stitial infiltrates are common, pleural effu-
sions can occur, but none of the radiographic 
findings associated with M. pneumoniae 
CAP are specific.1
NONRESPONSE TO EMPIRICAL 
β-LACTAM ANTIBIOTICS
The British Thoracic Society guide-
lines1 recommend amoxicillin as first choice 
for oral antibiotic therapy in children with 
suspected bacterial CAP. They also advise 
that macrolide antibiotics may be added at 
any age in case of very severe disease or if 
there is no response to first-line empirical 
treatment. In children with CAP who do 
not recover within a few days as would be 
expected in viral infection, and who do not 
respond to β-lactam antibiotics, clinicians 
should consider M. pneumoniae CAP.
DIAGNOSTIC TESTS
Diagnostic tests – the science in diag-
nosing M. pneumoniae infection
Children with moderate-to-severe CAP 
and/or presence of risk factors (underlying dis-
ease or immunodeficiency) should be referred 
to secondary care for further assessment.1 
Microbiologic diagnosis should be attempted 
in those children. Current guidelines1,3 recom-
mend PCR and serologic tests to diagnose M. 
pneumoniae infections. An overview of diag-
nostic tests is shown in Table 1.
PCR
PCR is considered as the new “gold 
standard” with a superior sensitivity and 
shorter turnaround time than culture. Nucleic 
acid amplification techniques for the detec-
tion of M. pneumoniae DNA or RNA differ 
in the choice of target genes used (e.g., P1 
gene, 16S rDNA, 16S rRNA etc.), (PCR vs. 
isothermal amplification techniques), and 
detection formats (conventional vs. real-
time, monoplex vs. multiplex). In the recent 
past, research focused on the evaluation of 
commercially available tests,5,14 multiplex 
assays,14 and strain typing methods.5
Importantly, like many other respira-
tory pathogens, M. pneumoniae can be car-
ried in the upper respiratory tract of asymp-
tomatic children. Detection rates in children 
without symptoms of a respiratory tract 
infection vary from 3% or less to 56%.2,5,15 
It appears that the mere presence of M. pneu-
moniae in the upper respiratory tract may not 
necessarily indicate respiratory disease.15
CULTURE
Culture is not used for routine diagno-
sis because it is labor-intensive, needs special 
enriched broth or agar media, and the incuba-
tion period can take up to 3 weeks.
RAPID ANTIGEN TEST
Rapid antigen tests have a limited 
sensitivity because of a detection limit of 
approximately 1 × 103 colony-forming units 
(CFU)/ml.5,16 Although they have a lower 
sensitivity than PCR, the detection time is 
faster and only less-trained staff is required 
compared with culture.
SEROLOGY
The sensitivity of specific serologic 
tests depends on the time point of the first 
serum sample and on the availability of paired 
sera collected ≥ 2 weeks apart to evaluate 
seroconversion and/or ≥ 4-fold antibody titer 
increase (“gold standard”). Specific serum 
immunoglobulin (Ig) M can be detected 
within 1 week after initial infection and about 
1–2 weeks before IgG.10 Reinfection in adults 
can lead directly to an IgG response and may 
lack production of IgM. Specific serum IgA 
rises, peaks and decreases earlier than IgM, 
but is less frequently detected.15
The previously used serologic tests are 
complement fixation tests, particle agglutina-
tion assays, and immunofluorescent assays, 
which were based on crude M. pneumoniae 
antigen extracts. Since M. pneumoniae con-
tains large amounts of glycolipids that elicit 
cross-reactive antibody responses (manuscript 
submitted), enrichment for adhesion protein 
P1 or protein extracts without glycolipid anti-
gens has been used to improve the test perfor-
mance of enzyme immunoassays (EIAs).
Intriguingly, one study reported that 
IgM as well as IgG and IgA could be detected 
by EIA in single serum samples of asymp-
tomatic M. pneumoniae PCR-positive chil-
dren.15 The antibody response in these children 
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may simply reflect a previous encounter with 
M. pneumoniae and is not necessarily related 
to the concurrent presence of M. pneumoniae 
in the upper respiratory tract.
Overall, no single diagnostic test or 
combination of tests is capable of differen-
tiating carriage from infection in a clinically 
relevant time frame.
ANTIBODY-SECRETING CELL 
RESPONSE
The humoral immune response is 
highly specific for the infecting pathogen. 
However, the use of convalescent sera is 
not helpful in clinical settings, because of 
the time delay that is inevitable when wait-
ing for a titer increase. The specific B cell 
response is more rapid and short-lived, 
and thus an optimal target for determin-
ing infectious etiology in CAP patients.17 
It can be detected by measuring antibody-
screening cells (ASCs) with an enzyme-
linked immunospot assay. A recent study 
found that M. pneumoniae-specific ASCs 
indeed circulate in peripheral blood only 
during CAP, while serum antibodies remain 
at high levels over months (unpublished 
data). The detection of ASCs could there-
fore potentially serve as a future diagnostic 
tool discriminating M. pneumoniae infec-
tion from carriage.
In conclusion, clinicians need to be 
aware of the implications and clinical signifi-
cance of a positive PCR and/or serology test 
result for M. pneumoniae. Rather than rely-
ing on diagnostic test results alone, clinicians 
need to interpret these results in combination 
with clinical features and a lack of response 
to β-lactam antibiotics.
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TABLE 1. Overview of Diagnostic Tests for M. pneumoniae
Method Test Target/Antigen Antibodies/Cells Specimen(s) Performance Diagnostic Value
Direct detection  
of M.  pneumoniae
PCR Different target genes 
(e.g., P1 gene, 16S 
rDNA, 16S rRNA)
— Respiratory 
specimen, 
other bod-
ily fluids or 
tissues
High sensitivity, high specificity Routine
Rapid antigen 
test
Different antigens 
(e.g., adhesion 
protein P116)
— Respiratory  
specimen
Moderate-high sensitivity,  
moderate-high specificity
(Routine)*
Culture — — Respiratory  
specimen
Low sensitivity, high specificity Advanced
Nonspecific sero-
logic tests for  
M. pneumoniae
Cold agglutinin 
test (“bedside 
test”)
Erythrocytes (I 
antigen)
Cold agglutinins 
(IgM)
Serum Low sensitivity, low specificity (Routine)†
Specific serologic 
tests for M. 
 pneumoniae
CFT Antigen extracts with 
glycolipids and/or 
proteins
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tion between 
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Serum Less sensitive and less specific  
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comparable with EIA
(Routine)‡
IFA    Less sensitive and less specific than 
EIA (subjective interpretation)
(Routine)‡
EIA Proteins (e.g., adhe-
sion protein P1) 
and/or glycolipids
IgM, IgG, IgA Serum Moderate-high sensitivity,
Moderate-high specificity
Routine
Immunoblotting    High sensitivity, high specificity  
(confirmatory assay)§
Advanced
Specific ASC 
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Blood 
(PBMCs)
High sensitivity, high specificity 
(unpublished data)
Advanced
*Not available worldwide.
†Historical test: cold agglutinins are IgM antibodies that target the I antigen of human erythrocytes during M. pneumoniae infection and precipitate when a blood sample is placed 
in an anticoagulated tube on ice for around 30 seconds; replaced by specific serologic tests.
‡Largely replaced by EIA.
§Dumke et al. Diagn Microbiol Infect Dis 2012;73:200–203.
CFT, complement fixation test; ELISpot, enzyme-linked immunospot assay: IFA, immunofluorescent assay; Ig, immunoglobulin; PA, particle agglutination; PBMC, peripheral blood 
mononuclear cell.
Table adapted from Meyer Sauteur et al.10
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